上海三友医疗器械股份有限公司 关于实际控制人及其一致行动人减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 基本情况 证券代码：688085 证券简称：三友医疗 公告编号：2026-010 本次减持计划实施前，上海三友医疗器械股份有限公司（以下简称"公司"） 实际控制人之一、董事兼总裁徐农先生的一致行动人混沌天成资管－徐农－混沌 天成精选策略 18 号单一资产管理计划（以下简称"混沌天成 18 号"）直接持有 公司股份 2,212,155 股，占公司总股本 0.66%，上述股份来源包含大宗交易取得 的股份及资本公积转增股本获得的股份；徐农先生直接持有公司股份 39,297,975 股。公司实际控制人之一、董事长 Michael Mingyan Liu（刘明岩） 先生直接持有公司股份 30,341,922 股，占公司总股本 9.10%，上述股份来源包 含公司首次公开发行股票并上市前持有的公司股份及对应股份资本公积转增股 本获得的股份和集中竞价交易取得及对应股份资本公积转增股本获得的 ...

重要内容提示： | 权益变动方向 | 比例增加□ | 比例减少☑ | | --- | --- | --- | | 权益变动前合计比例 | 26.45% | | | 权益变动后合计比例 | 25.00% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否☑ | | 是否触发强制要约收购义务 | 是□ | 否☑ | 证券代码：688085 证券简称：三友医疗 公告编号：2026-009 上海三友医疗器械股份有限公司 关于实际控制人及其一致行动人权益变动触及 5% 整数倍的提示性公告 公司实际控制人及其一致行动人保证向本公司提供的信息真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 二、 权益变动触及 5%整数倍的基本情况 近日，上海三友医疗器械股份有限公司（简称"公司"）收到 Michael Mingyan Liu（刘明岩）先生及徐农先生出具的《告知函》，2026 年 2 月 4 日至 2026 年 3 月 11 日，Michael Mingyan Liu（刘明岩）先生通过 ...

上市公司名称：上海三友医疗器械股份有限公司 股票上市地点：上海证券交易所 股票简称：三友医疗 股票代码：688085 信息披露义务人 1：徐农（本人及一致行动人"混沌天成资管－徐农－混沌天成 精选策略 18 号单一资产管理计划"） 通讯地址：上海市嘉定区* 信息披露义务人 2：Michael Mingyan Liu（刘明岩） 通讯地址：上海市嘉定区* 信息披露义务人 3：David Fan（范湘龙） 通讯地址：上海市嘉定区* 股权变动性质：股份减持（以上信息披露义务人为一致行动人，合计持股比例减 少至 25%。） 签署日期：2026 年 3 月 11 日 上海三友医疗器械股份有限公司 简式权益变动报告书 声 明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权 益变动报告书》等相关法律法规编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》等相关规定， 本报告书已全面披露信息 ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on companies with validated platforms and effective innovative drugs, indicating a positive outlook for certain segments within the industry [2]. Core Insights - The pharmaceutical and biotechnology sectors are experiencing a shift towards a multi-layered overseas strategy, with Chinese companies increasingly recognized by global multinational corporations (MNCs) for their research capabilities and technology platforms [2]. - Recent significant business development (BD) deals include China National Pharmaceutical Group's exclusive licensing agreement for the drug Rovabatinib worth $1.53 billion and the collaboration between Deqi Pharmaceutical and UCB for the CD19/CD3 bispecific T cell engager ATG-201, valued at over $1.18 billion [2][10]. - The report highlights the performance of the in vitro diagnostics sector, which was the only sub-sector to see a gain of 0.18%, while other segments like medical device and vaccine sectors faced declines [7][8]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 2.78% from March 2 to March 6, underperforming the Wind All A index (-2.3%) and the CSI 300 index (-1.07%) [7]. - Notable stock performances included Yahui Pharmaceutical (+38.1%), Zhejiang Pharmaceutical (+12.8%), and Zhongyuan Xiehe (+12.7%) as top gainers, while Tianzhihang-U (-14.8%), Furui Medical (-13.1%), and Haoyuan Pharmaceutical (-12.3%) were the biggest losers [10]. Industry News and Key Company Announcements - On March 6, Xianweida Biopharmaceutical and Pfizer announced the approval of a new indication for their GLP-1 receptor agonist, Enoglutide, for long-term weight management in adults [10]. - China National Pharmaceutical Group's licensing agreement for Rovabatinib includes a $135 million upfront payment and potential milestone payments based on sales performance [10]. - Deqi Pharmaceutical's agreement with UCB for ATG-201 includes an upfront payment of $80 million and potential milestone payments exceeding $1.1 billion [10]. - Wanbangde reported a significant increase in net profit for Q1 2026, reaching 165 million yuan, a year-on-year growth of 985.4% [11].

Investment Rating - The overall industry rating is neutral, indicating that the expected return over the next six months will be between -5% and 5% relative to the CSI 300 index [6][7]. Core Insights - The pharmaceutical sector experienced a decline of 1.12% on March 4, 2025, outperforming the CSI 300 index by 0.02 percentage points, ranking 26th among 31 sub-industries in the Shenwan classification [3]. - Notable performers in the sector included Yahui Pharmaceutical (+20.02%), Ailis (+11.17%), and Rundou Co. (+6.99%), while the worst performers were Kanghui Co. (-6.26%), Changshan Pharmaceutical (-5.89%), and Hualan Biological (-4.75%) [3]. - Priovant announced that the FDA has accepted its new drug application for Brepocitinib, granting it priority review status based on positive results from the Phase 3 VALOR study, which showed significant clinical improvement in myositis total improvement score (TIS) for the 30mg dose group [4]. Summary by Sections Market Performance - On March 4, 2025, the pharmaceutical sector's performance was -1.12%, with various sub-industries showing mixed results, including in vitro diagnostics (-0.62%) and hospitals (-0.72%) performing better than blood products (-2.16%) and offline pharmacies (-2.10%) [3]. Industry News - The FDA has accepted Priovant's application for Brepocitinib, a selective TYK2 and JAK1 dual inhibitor, which could become the first targeted therapy approved for dermatomyositis if successful [4]. - Sanyou Medical announced that its SWINGO-3D Lumbar Cage System received FDA 510(K) certification [4]. Company News - Cap Bio's subsidiary received a medical device registration certificate for its chromosome multi-STR genotyping kit [5]. - Jiukang Bio announced the approval of its blood type identification and irregular antibody screening quality control product by the National Medical Products Administration [5]. - Dongya Pharmaceutical received approval for its fumaric acid valproate tablets from the National Medical Products Administration [5].

证券代码：688085 证券简称：三友医疗 公告编号：2026-008 上海三友医疗器械股份有限公司 1、获批主体：Implanet 2、产品名称：SWINGO-3D Lumbar Cage System 3、应用领域：SWINGO-3D Lumbar Cage System（3D 打印腰椎椎间融合系统） 旨在与辅助内固定系统配合使用，适用于患有退行性椎间盘疾病的骨骼成熟的患 者。有以下适应症：患有 L2 至 S1 节段一个或两个连续水平的退行性椎间盘疾病 （定义为背痛椎间盘源性，病史和放射学研究证实椎间盘变性）；脊椎滑脱。 SWINGO-3D Lumbar Cage System（3D 打印腰椎椎间融合系统）包含三种不同型 号的融合系统——SWINGO PLIF 腰椎椎间融合系统、SWINGO TLIF 腰椎椎间融合 系统、SWINGO LLIF 腰椎椎间融合系统，可适用于多种手术入路方式。 4、授权范围：美国 5、使用期限：无有效期 6、上市编号：K254017 关于控股公司 Implanet 公司 3D 打印腰椎椎间融合系 统获得美国 FDA510（K）认证的自愿披露公告 本公司董事会及全体董事保证本公 ...

三友医疗：发布2025年业绩快报，业绩符合预期，接近预告区间中位数 2025年公司实现收入5.43亿元（业绩预告5.35亿元-5.62亿元），同比增长19.66%；实现归母净利润0.63亿元（业绩 预告0.56亿元-0.73亿元），同比增长451.85%；实现扣非归母净利润0.50亿元（业绩预告0.43亿元-0.61亿元），同 比实现扭亏为盈。 据此计算，2025Q4收入约1.51亿元（+25 三友医疗：发布2025年业绩快报，业绩符合预期，接近预告区间中位数 2025年公司实现收入5.43亿元（业绩预告5.35亿元-5.62亿元），同比增长19.66%；实现归母净利润0.63亿元（业绩 预告0.56亿元-0.73亿元），同比增长451.85%；实现扣非归母净利润0.50亿元（业绩预告0.43亿元-0.61亿元），同 比实现扭亏为盈。 据此计算，2025Q4收入约1.51亿元（+25%），归母净利润约131万元（-52%），扣非归母净利润约32万元，上年 同期为-647万元。 业绩变化主要原因： 1）2025年公司在带量采购全面执行的压力下，利用自身创新疗法优势，不断进行新产品的开发和合作，进一步丰 富和增加 ...

Core Viewpoint - Sanyou Medical reported a significant increase in its 2025 performance, with total revenue reaching 543 million yuan, representing a year-on-year growth of 19.66%, and a net profit attributable to shareholders of 63.29 million yuan, which is an increase of 451.85% [1] Group 1 - The growth in performance is primarily attributed to the company's continuous development of new products leveraging innovative therapies and deepening strategic partnerships [1] - The company has enriched its product line and advanced channel penetration, effectively driving stable sales growth [1] - The ultrasound bone knife business has rapidly expanded, and international operations have seen swift development, with the subsidiary Implanet achieving revenue of 12.47 million euros, a year-on-year increase of 32.62% [1]

Financial Performance - The company achieved total operating revenue of 542.79 million yuan, representing a year-on-year increase of 19.66% [3] - Research and development expenses amounted to 83.71 million yuan, accounting for 15.42% of total revenue [3] - The net profit attributable to the parent company was 63.29 million yuan, a significant increase of 451.85% year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 49.67 million yuan, marking a turnaround from loss to profit compared to the previous year [3] Business Development - The company leveraged its innovative therapy advantages to develop new products and expand its product line, leading to stable sales growth [4] - The ultrasound knife business experienced rapid growth in both sales and net profit during the reporting period [4] - The international business continued to grow rapidly, with the subsidiary Implanet achieving operating revenue of 12.47 million euros, a year-on-year increase of 32.62%, particularly strong in the U.S. market with a growth of 49.30% [4] Financial Position - As of the end of the reporting period, total assets were 2,376.83 million yuan, an increase of 3.04% from the beginning of the period [3] - The equity attributable to the parent company was 2,104.89 million yuan, reflecting a 10.10% increase from the beginning of the period [3] Shareholder Equity - The company implemented a capital reserve transfer plan, increasing the share capital by 34.22% during the reporting period [7] - The increase in share capital was due to the transfer of 2 shares for every 10 shares held and the completion of the acquisition of remaining minority shares of the subsidiary [7]

2025年，超声骨刀业务在销售业绩和净利润上均取得了快速的增长。公司国际化业务亦保持持续快速发 展。 三友医疗(688085.SH)披露2025年度业绩快报，公司实现营业总收入5.43亿元，同比增长19.66%;研发费 用8371.08万元，研发投入占比15.42%;实现归属于母公司所有者的净利润6328.95万元，同比增加 451.85%;实现归属于母公司所有者的扣除非经常性损益的净利润4966.71万元，与上年同期相比，实现 扭亏为盈。 ...